Nab-P/carboplatin in squamous NSCLC: Outcomes in elderly

Speaker: Egbert Smith

E. Smit elaborates the results of the clinical study of nab-Paclitaxel plus carboplatin in advanced squamous NSCLC with a focus on elderly patients. He underlines that this patient population is more prone to toxicities and comorbidities present additional problem. He argues for performing clinical studies in this setting. 

Discussion Points

  • A rational for the abstract presented at ELCC 2016 (16PD) nab-Paclitaxel + carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology
  • Main results of the study
  • The findings perspective
  • Importance of designing clinical studies in elderly patients